סביבו

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

TELBIVUDINE 600 MG

Disponible depuis:

NOVARTIS PHARMA SERVICES AG

Code ATC:

J05AF11

forme pharmaceutique:

FILM COATED TABLETS

Mode d'administration:

PER OS

Fabriqué par:

NOVARTIS PHARMA STEIN AG, SWITZERLAND

Groupe thérapeutique:

TELBIVUDINE

indications thérapeutiques:

Treatment of chronic hepatitis B in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.The following points should be considered when initiating therapy with Sebivo:- For HBeAg - positive patients, Sebivo treatment should only be initiated in patients with baseline HBV DNA < 9log 10 copies/ml and baseline ALT>or= 2x ULN.- For HBeAg - negative patients, Sebivo treatment should only be initiated in patients with baseline HBV DNA < 7log 10 copies/ml.

Date de l'autorisation:

2012-12-01